GLP-1 RAs Enhance AMPK Signaling in Alzheimer’s Disease
Scientific paper explores the potential therapeutic benefits of GLP-1 receptor agonists (GLP-1RAs) for Alzheimer’s disease (AD), building on the known link between type 2 diabetes and increased AD risk. The research indicates that GLP-1 levels are lower in AD, correlating negatively with amyloid-beta (Aβ) levels in patients. Through experiments in transgenic mice and cell lines, the authors […]
US Chronic Disease Burden Versus Peers
There is a significant burden of chronic diseases in the United States, comparing its rates to other developed nations. One source from the Peterson-KFF Health System Tracker points out that the U.S. has higher rates of many chronic illnesses, including obesity, diabetes, and asthma, compared to its peers, contributing to higher death rates and shorter life expectancy. The […]
GLP-1 RA Cessation and Weight Regain
This systematic review and meta-analysis investigated the rate of weight regain after people stopped using GLP-1 receptor agonists (GLP-1 RAs) for weight management. The researchers identified relevant studies and analyzed the weight loss achieved during treatment and the subsequent weight increase once medication stopped. Their findings indicate that participants regain a significant amount of weight relatively quickly after discontinuing GLP-1 RAs, with weight potentially returning to baseline within two […]
Global Risk Factors for Disease Burden, 1990–2021
Global burden and strength of evidence for 88 risk factors in204 countries and 811 subnational locations, 1990–2021 : a systematic analysis for the Global Burden of Disease Study 2021 Lancet May 18, 2024 GBD 2021 Risk Factors Collaborators. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, […]
Oral GLP-1 Analogs for Obesity Treatment
ADVANCEMENTS IN GLP-1 ANALOG FORMULATION DEVELOPMENT: OVERCOMING CHALLENGES IN ORAL DELIVERYFebruary 14, 2025By Adare Pharmaceuticals Obesity is a significant global health challenge that requires lifestyle changes and effective pharmacological treatments to overcome. Human glucagon-like peptide 1 (GLP-1) analogs, also called incretin mimetics, have emerged as a promising obesity treatment option. Additionally, oral GLP-1 formulations represent a […]
Boosting Muscle and Fat Loss with GLP-1s
This talk at the discuss the development of new medications designed to address muscle loss that can occur alongside weight loss achieved with GLP-1 receptor agonists like semaglutide and tirzepatide. While these powerful weight loss drugs are effective, a significant portion of the lost weight is lean body mass, raising concerns about potential long-term effects on physical function and health. Several investigational drugs, including SARMs and antimostatin agents, […]
Semaglutide and Lower Fracture Risk Versus Sleeve Gastrectomy
According to an article in Medscape Medical News, a study presented at the AACE 2025 conference indicates that individuals treated for obesity using semaglutide (Wegovy) may experience a significantly lower risk of fractures compared to those who undergo sleeve gastrectomy. Researchers utilized electronic health record data and observed a 26% reduction in fracture risk for the semaglutide group over a three-year period. The study […]
News Article – How to make your own GLP-1 drugs at home.
Are you wanting to save some money? Discouraged by the high price of the GLP-1 drugs from the big pharmaceutical companies and the compounding pharmacies? Here is an overview of what to expect in creating your own personal drug company. Both semaglutide and tirzepatide are GLP-1 RA (Glucose-like Peptide-1 Receptor Agonists). Agonists means that they […]
Weight-Loss Drugs’ Environmental Cost
Experts warn that current methods of making the peptide drugs are environmentally unfriendly April 28, 2024 by Aayushi Pratap Chemical & Engineering News, Volume 102, Issue 13 This article explores the significant environmental challenges associated with the rapidly increasing production of popular peptide-based weight-loss drugs like Wegovy and Zepbound. It highlights that current manufacturing methods, primarily solid-phase peptide […]
Review Article – Precision Medicine for Obesity Pharmacotherapy
Anazco D, Acosta A. Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy. Int J Obes (Lond). 2025 Mar;49(3):452-463. doi: 10.1038/s41366-024-01599-z. Epub 2024 Aug 10. PMID: 39127792; PMCID: PMC11931505. Published 10 August 2024 This review article explores the potential of precision medicine to improve obesity management, moving away from the current trial-and-error approach for selecting medications. […]